# Tesamorelin Mechanism of Action: The GH/IGF-1 Axis | RX Tesa > Tesamorelin mechanism of action: it binds the GHRH receptor on pituitary somatotrophs, drives cAMP/PKA signaling, and stimulates pulsatile growth hormone that raises hepatic IGF-1 and visceral-fat lipolysis. Receptor to cascade to hormone to growth factor to fat — the GHRH-analogue mechanism drawn as the stepped chain it actually is. ## In plain English The tesamorelin mechanism of action is a relay. Tesamorelin docks onto a receptor on hormone-making cells in the pituitary gland, flips a chemical switch inside those cells, and tells them to release the body's own growth hormone in natural bursts. That growth hormone travels to the liver and makes it produce IGF-1 (a growth signal the liver makes when growth hormone rises). Growth hormone and IGF-1 together tell fat cells — mostly the deep belly fat — to break down their stored fat. The short version: tesamorelin does not give you growth hormone, it convinces your body to make more of its own. ## Step one: tesamorelin binds the GHRH receptor Tesamorelin binds the growth hormone-releasing hormone receptor (GHRH-R), a Gs-coupled G-protein-coupled receptor sitting on the surface of pituitary somatotrophs — the cells whose job is to make and release growth hormone [4][7]. Native GHRH does the same thing, but it is destroyed within minutes by the enzyme DPP-IV. Tesamorelin's N-terminal trans-3-hexenoic acid modification blocks that cleavage, so the analogue keeps signaling long after natural GHRH would have been inactivated [8]. Adding that group to Tyr1 of human GRF(1-44) rendered the molecule resistant to DPP-IV deactivation and slowed its degradation in rat, dog, and human plasma [8]. ## Step two: the Gs/cAMP/PKA cascade Receptor binding activates adenylyl cyclase through the Gs protein, raising intracellular cAMP (cyclic AMP, a small molecule cells use as a "second messenger" to relay a signal from the surface inward). cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB. Phosphorylated CREB drives transcription of the growth-hormone gene and triggers exocytosis of GH-containing granules [4]. In plainer terms: the receptor flips a switch, the switch raises a chemical messenger, the messenger turns on an enzyme, and the enzyme both makes new growth hormone and releases the stockpile already loaded in the cell. A population pharmacokinetic-pharmacodynamic analysis confirmed that the result is episodic — tesamorelin stimulates growth hormone in pulses, not a flat continuous rise, and the model linked subcutaneous exposure to the GH and IGF-1 response [7]. Preserving that pulsatile rhythm matters: the body's natural growth-hormone secretion is bursty, and amplifying the existing bursts is mechanistically different from flooding the system with a continuous supply, which is the distinction from recombinant growth hormone. ## How does tesamorelin stimulate growth hormone release? Through the Gs-coupled GHRH-receptor cascade — adenylyl cyclase, cAMP, PKA, then CREB phosphorylation — which drives GH gene transcription and granule release in an episodic, pulsatile pattern. PK-PD modeling confirmed the secretion is pulsatile rather than continuous [7]. In 13 healthy men, two weeks of dosing raised mean overnight growth hormone by 0.5 ug/L (P=0.004) [4]. ## Step three: growth hormone raises IGF-1 The released growth hormone reaches the liver and activates JAK2/STAT5 signaling, which drives synthesis and secretion of IGF-1 [4]. IGF-1 is the durable readout of the whole cascade. In 13 healthy men, tesamorelin 2 mg/day for two weeks raised IGF-1 by 181 ug/L (P<0.0001) [4]; in the pivotal HIV trial IGF-1 rose 81.0% [1]. ## Does tesamorelin raise IGF-1 levels? Yes. Two independent human datasets show it clearly: +181 ug/L in 13 healthy men over two weeks (P<0.0001) [4], and +81.0% in the 412-patient pivotal HIV trial [1]. The IGF-1 elevation persists across the once-daily dosing interval even though the parent peptide clears from plasma quickly, which is why the effect is biologically sustained [7]. ## Step four: IGF-1 and GH drive visceral lipolysis Growth hormone and IGF-1 together activate hormone-sensitive lipase (the enzyme that releases stored fat from fat cells) and promote lipolysis preferentially in visceral adipose tissue [1]. The selectivity for deep abdominal fat over subcutaneous fat is what distinguishes the metabolic profile from recombinant growth hormone. A study of inflammatory markers in HIV patients found that tesamorelin reduced tissue plasminogen activator antigen and modestly raised adiponectin, and that the change in inflammatory markers correlated with the degree of visceral-fat reduction — pointing to visceral fat itself as the mediator rather than a direct drug effect [11]. That correlation is the mechanistic keystone. It says the downstream metabolic improvements track how much visceral fat was lost, not how much drug was given — exactly what a GH/IGF-1-driven lipolysis model predicts, and the reason the whole cascade reads as one connected chain from receptor to fat cell [11][1]. It is also why the effect reverses when dosing stops: remove the upstream signal and the visceral fat reaccumulates, taking the inflammatory and metabolic improvements with it [2]. ## Route studied: subcutaneous injection The only route studied in the clinical trials and the only approved route is subcutaneous injection into the abdomen [1][3]. A non-clinical study did test pulmonary (inhaled dry-powder) delivery in dogs, reporting 41% bioavailability relative to subcutaneous injection, but that route never advanced to the approved product [9]. No oral formulation reached approval; the peptide would not survive digestion. ## How does tesamorelin work? It binds the GHRH receptor on pituitary somatotrophs, raises cAMP, and stimulates pulsatile release of the body's own growth hormone, which in turn drives hepatic IGF-1 and visceral-fat lipolysis [4][7][1]. It works upstream — on the gland that makes the hormone — not by supplying the hormone itself. ## Is tesamorelin a growth hormone? No. It is a synthetic GHRH analogue that prompts the pituitary to secrete endogenous growth hormone. It does not supply growth hormone directly, which is the key difference from recombinant GH; the body's own pulsatile rhythm is amplified rather than overridden [4][7]. --- A shadowless data sheet of the tesamorelin record — the GHRH-receptor cascade and the visceral-fat numbers logged to source, the FDA approval marked exactly where it stops and the off-label boundary left in plain view; no clinic behind the grid and nothing here dispensed or sold.